benitec's law, page-10

Coolstocks. I dont see that it requires manic buying. A continued rerate is justified imo. A successful Hep C trial resulting in a cure apparently values BLT north of $80 per share. BLT stated in their report yesterday they have the cure so risk is largely mitigated, but understand it still needs to go through the normal process. The market has only attributed a 2.5% success rate at current SP which I believe will very quickly adjust to between 5 and 10% or $4-$8 per share. Expecting at least $4 dollar range in March. Even this attributes no value to the additional existing pipeline of projects, all of which will be validated if positive news emerges from this trial, which I think is exactly what will happen. Expecting a couple of very strong trading days next week. Bought another 27500 units at $1.995 yesterday.